Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Last updated: May 28, 2025
Sponsor: ITM Solucin GmbH
Overall Status: Active - Not Recruiting

Phase

3

Condition

Abdominal Cancer

Digestive System Neoplasms

Carcinoid Syndrome And Carcinoid Tumours

Treatment

CAPTEM (Capecitabine and Temozolomide)

Everolimus

FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)

Clinical Study ID

NCT04919226
DP-1111-02CT
  • Ages > 18
  • All Genders

Study Summary

The purpose of the study is to evaluate the efficacy, safety & patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients aged ≥ 18 years.

  • Histologically confirmed diagnosis of unresectable, well-differentiatedGastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs). measurable site of diseaseper RECIST v1.1 (Response evaluation criteria in solid tumors) using contrastcomputed tomography (CT) / magnetic resonance imaging (MRI).

  • Somatostatin receptor-positive (SSTR+) disease.

Exclusion

Exclusion Criteria:

  • Known hypersensitivity to Lutetium 177Lu, edotreotide, DOTA (dodecane tetraaceticacid), any of the comparators, or any excipient or derivative (e.g. rapamycin).

  • Prior (Peptide Receptor Radionuclide Therapy) PRRT.

  • Any major surgery within 4 weeks prior to randomization in the trial.

  • Therapy with an investigational compound and/or medical device within 30 days or 7half-life periods (whichever is longer) prior to randomization.

  • Other known malignancies.

  • Serious non-malignant disease.

  • Renal, hepatic, cardiovascular, or hematological organ dysfunction, potentiallyinterfering with the safety of the trial treatments.

  • Pregnant or breastfeeding women.

  • Patients not able to declare meaningful informed consent on their own or any othervulnerable population to that.

Study Design

Total Participants: 259
Treatment Group(s): 5
Primary Treatment: CAPTEM (Capecitabine and Temozolomide)
Phase: 3
Study Start date:
December 21, 2021
Estimated Completion Date:
September 30, 2027

Connect with a study center

  • Royal North Shore Hospital

    St. Leonards, New South Wales 2065
    Australia

    Site Not Available

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria VIC 3000
    Australia

    Site Not Available

  • Fudan University Shanghai Cancer Center

    Shanghai, 200000
    China

    Site Not Available

  • Affiliated Hospital of Jiangnan University

    Wuxi, 214122
    China

    Site Not Available

  • Haut-Leveque Hospital, Department of Hepatogastroenterology and Digestive Tract Oncology

    Pessac, Bordeaux 33604
    France

    Site Not Available

  • Nantes University Hospital Center - Hotel Dieu Hospital

    Nantes, Cedex 44093
    France

    Site Not Available

  • Edouard Herriot Hospital, Medical Oncology Unit

    Lyon, 69003
    France

    Site Not Available

  • IUCT Oncopole - Institut Universitaire du Cancer de Toulouse

    Toulouse, 31059
    France

    Site Not Available

  • Charite - University Hospital Berlin

    Berlin, 13353
    Germany

    Site Not Available

  • University Hospital Bonn, Department of Nuclear Medicine

    Bonn, 53127
    Germany

    Site Not Available

  • University Hospital Erlangen, Department of Internal Medicine I - Endocrinology

    Erlangen, 91054
    Germany

    Site Not Available

  • University Duisburg-Essen, University Hospital Essen, Clinic for Nuclear Medicine

    Essen, 45147
    Germany

    Site Not Available

  • All India Institute Of Medical Sciences, Nuclear Medicine

    New Delhi, Delhi 110029
    India

    Site Not Available

  • HCG Cancer Centre, Medical Oncology

    Bangalore, Karnataka 560027
    India

    Site Not Available

  • Tata Memorial Hospital, Nuclear Medicine & Molecular Imaging

    Mumbai, 400012
    India

    Site Not Available

  • University Polyclinic Hospital "G. Martino", Department of Biomedical Sciences, Dentistry and Morphological and Functional Imaging, Complex Operational Unit of Nuclear Medicine

    Messina, 98125
    Italy

    Site Not Available

  • European Institute of Oncology (IEO), IRCCS

    Milan, 20141
    Italy

    Site Not Available

  • University Hospital "Federico II", Department of Molecular and Clinical Endocrinology and Oncology

    Naples, 80131
    Italy

    Site Not Available

  • University Polyclinic Foundation "Agostino Gemelli" - IRCCS, Complex Operative Unit of Medical Oncology

    Rome, 00168
    Italy

    Site Not Available

  • VU Medical Center (VUMC), Department of Medical Oncology

    Amsterdam, 1081-HV
    Netherlands

    Site Not Available

  • Erasmus University Medical Center Rotterdam

    Rotterdam, 3015 GD
    Netherlands

    Site Not Available

  • ICO Hospitalet, Catalan Institute of Oncology

    Barcelona, 199-203
    Spain

    Site Not Available

  • University Hospital Vall d'Hebron, Department of Medical Oncology

    Barcelona, 08035
    Spain

    Site Not Available

  • University General Hospital Gregorio Maranon

    Madrid, 28007
    Spain

    Site Not Available

  • University Hospital 12 de Octubre, Department of Gastroenterology

    Madrid, 28041
    Spain

    Site Not Available

  • Central University Hospital de Asturias (HUCA), IUOPA - Universitary Institute of Oncology

    Oviedo, 33011
    Spain

    Site Not Available

  • University Hospital Complex of Santiago (CHUS)

    Santiago De Compostela, 15706
    Spain

    Site Not Available

  • University and Polytechnic Hospital La Fe, Endocrinology

    Valencia, 46026
    Spain

    Site Not Available

  • Uppsala University Hospital, Department of Oncology

    Uppsala, 75185
    Sweden

    Site Not Available

  • King's College Hospital

    London, SE5 9RS
    United Kingdom

    Site Not Available

  • Royal Free Hospital

    London, NW3 2QG
    United Kingdom

    Site Not Available

  • Stanford Cancer Center

    Palo Alto, California 94305
    United States

    Site Not Available

  • University of Colorado Hospital, Nuclear Medicine

    Aurora, Colorado 80045
    United States

    Site Not Available

  • H. Lee Moffitt Cancer Center & Research Institute

    Tampa, Florida 33612
    United States

    Site Not Available

  • Dana Farber Cancer Institute

    Boston, Massachusetts 02215
    United States

    Site Not Available

  • Mayo Clinic - Rochester, Department of Oncology

    Rochester, Minnesota 55905
    United States

    Site Not Available

  • Washington University Alvin J. Siteman Cancer Center

    Saint Louis, Missouri 63110
    United States

    Site Not Available

  • ICAHN School of Medicine at Mount Sinai, Tish Cancer Institute

    New York, New York 10128
    United States

    Site Not Available

  • Memorial Sloan-Kettering Cancer Center

    New York, New York 10065
    United States

    Site Not Available

  • Duke University School of Medicine, Duke Cancer Institute

    Durham, North Carolina 27710
    United States

    Site Not Available

  • Oregon Health and Science University

    Portland, Oregon 97239-3098
    United States

    Site Not Available

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania 19111-2497
    United States

    Site Not Available

  • Scott Paulson

    Dallas, Texas 75246
    United States

    Active - Recruiting

  • Texas Oncology

    Dallas, Texas 75246
    United States

    Site Not Available

  • University of Texas MD Anderson Cancer Center

    Houston, Texas 77030
    United States

    Site Not Available

  • University of Utah, Huntsman Cancer Institute

    Salt Lake City, Utah 84112
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.